Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stem cell-like reprogramming is required for leukemia-initiating activity in B-ALL.
Fregona V, Bayet M, Bouttier M, Largeaud L, Hamelle C, Jamrog LA, Prade N, Lagarde S, Hebrard S, Luquet I, Mansat-De Mas V, Nolla M, Pasquet M, Didier C, Khamlichi AA, Broccardo C, Delabesse É, Mancini SJC, Gerby B. Fregona V, et al. Among authors: largeaud l. J Exp Med. 2024 Jan 1;221(1):e20230279. doi: 10.1084/jem.20230279. Epub 2023 Nov 6. J Exp Med. 2024. PMID: 37930337 Free PMC article.
Germline PAX5 mutation predisposes to familial B-cell precursor acute lymphoblastic leukemia.
Duployez N, Jamrog LA, Fregona V, Hamelle C, Fenwarth L, Lejeune S, Helevaut N, Geffroy S, Caillault A, Marceau-Renaut A, Poulain S, Roche-Lestienne C, Largeaud L, Prade N, Dufrechou S, Hébrard S, Berthon C, Nelken B, Fernandes J, Villenet C, Figeac M, Gerby B, Delabesse E, Preudhomme C, Broccardo C. Duployez N, et al. Among authors: largeaud l. Blood. 2021 Mar 11;137(10):1424-1428. doi: 10.1182/blood.2020005756. Blood. 2021. PMID: 33036026 Free article. No abstract available.
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.
Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau ML, Rieu JB, Tavitian S, Huguet F, Picard M, Bories P, Vial JP, Lechevalier N, Béné MC, Luquet I, Mansat-De Mas V, Delabesse E, Récher C, Vergez F. Canali A, et al. Among authors: largeaud l. Clin Cancer Res. 2023 Jan 4;29(1):134-142. doi: 10.1158/1078-0432.CCR-22-2237. Clin Cancer Res. 2023. PMID: 36318706
The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, Juvin PY, Jamrog L, Bories P, Hébrard S, Lagarde S, Mansat-De Mas V, Dovey OM, Yusa K, Vassiliou GS, Jansen JH, Tekath T, Rombaut D, Ameye G, Barin C, Bidet A, Boudjarane J, Collonge-Rame MA, Gervais C, Ittel A, Lefebvre C, Luquet I, Michaux L, Nadal N, Poirel HA, Radford-Weiss I, Ribourtout B, Richebourg S, Struski S, Terré C, Tigaud I, Penther D, Eclache V, Fontenay M, Broccardo C, Delabesse E. Lafage-Pochitaloff M, et al. Among authors: largeaud l. Blood Adv. 2022 Jan 25;6(2):386-398. doi: 10.1182/bloodadvances.2021005311. Blood Adv. 2022. PMID: 34638130 Free PMC article.
Somatic genetic alterations predict hematological progression in GATA2 deficiency.
Largeaud L, Collin M, Monselet N, Vergez F, Fregona V, Larcher L, Hirsch P, Duployez N, Bidet A, Luquet I, Bustamante J, Dufrechou S, Prade N, Nolla M, Hamelle C, Tavitian S, Habib C, Meynier M, Bellanne-Chantelot C, Donadieu J, De Fontbrune FS, Fieschi C, Ferster A, Delhommeau F, Delabesse E, Pasquet M. Largeaud L, et al. Haematologica. 2023 Jun 1;108(6):1515-1529. doi: 10.3324/haematol.2022.282250. Haematologica. 2023. PMID: 36727400 Free PMC article.
More than ten percent of relapses occur after five years in AML patients with NPM1 mutation.
Bertoli S, Tavitian S, Bérard E, Mansat-De Mas V, Largeaud L, Gadaud N, Rieu JB, Vergez F, Luquet I, Huguet F, Sarry A, Delabesse E, Récher C. Bertoli S, et al. Among authors: largeaud l. Leuk Lymphoma. 2020 May;61(5):1226-1229. doi: 10.1080/10428194.2019.1706733. Epub 2020 Feb 5. Leuk Lymphoma. 2020. PMID: 32022605 No abstract available.
CD34+CD38-CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.
Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, Luquet I, Mas V, Largeaud L, Sarry A, Huguet F, Delabesse E, Bérard E, Récher C. Vergez F, et al. Among authors: largeaud l. Cancers (Basel). 2020 May 6;12(5):1174. doi: 10.3390/cancers12051174. Cancers (Basel). 2020. PMID: 32384744 Free PMC article.
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, Luquet I, De Mas V, Filleron T, Cassou M, Sarry A, Fornecker LM, Simand C, Bertoli S, Recher C, Delabesse E. Bories P, et al. Among authors: largeaud l. PLoS One. 2020 Oct 1;15(10):e0238795. doi: 10.1371/journal.pone.0238795. eCollection 2020. PLoS One. 2020. PMID: 33001991 Free PMC article.
44 results